Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pankaj Talwar

Internal Medicine Rockville, MD Medical Doctor

NPI 1174546410 CMS profile 234746

50 W Edmonston Dr, #401, Rockville, MD 20852

Open in the dashboard

General payments

$2,716

135 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pankaj Talwar of Rockville, MD is reported in the CMS Open Payments database as having received $2,716 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $190 10
2024 General $445 19
2023 General $358 18
2022 General $286 16
2021 General $762 37
2020 General $187 12
2019 General $490 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pankaj Talwar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pankaj Talwar were reported at $190. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pankaj Talwar Internal Medicine median Middle half National median
2019 $490 $159 $48–$570 $163
2020 $187 $119 $33–$402 $114
2021 $762 $135 $37–$521 $132
2022 $286 $141 $42–$496 $149
2023 $358 $149 $45–$519 $160
2024 $445 $154 $47–$537 $164
2025 $190 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $350 9 payments
  2. Novo Nordisk Inc $344 20 payments
  3. AbbVie, Inc. $313 21 payments
  4. Esperion Therapeutics, Inc. $221 6 payments
  5. Lilly USA, LLC $210 13 payments
  6. Amgen Inc. $156 8 payments
  7. Pfizer Inc. $114 7 payments
  8. Abbott Laboratories $114 6 payments
  9. Medtronic, Inc. $109 1 payment
  10. Exact Sciences Corporation $96 4 payments
  11. Other $687 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,710 134 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $289 17 payments
  2. RYBELSUS $232 13 payments
  3. NEXLETOL $221 6 payments
  4. UBRELVY $219 14 payments
  5. FARXIGA $159 4 payments
  6. AIRSUPRA $145 3 payments
  7. NEXLIZET $125 1 payment
  8. JARDIANCE $115 8 payments
  9. ELIQUIS $114 7 payments
  10. Otezla $113 6 payments
  11. Other $2,018 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,894

Median for Internal Medicine: 777

Drug cost

$237,638

Median for Internal Medicine: $73,373

Branded share of claims

15.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 31 $46,046
Ozempic Semaglutide Brand 20 $39,312
Januvia Sitagliptin Phosphate Brand 24 $36,166
Prolia Denosumab Brand 13 $21,988
Jardiance Empagliflozin Brand 21 $19,256
Farxiga Dapagliflozin Propanediol Brand 13 $14,437
Xarelto Rivaroxaban Brand 12 $10,503
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 15 $5,639
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 26 $4,045
Levemir Flexpen Insulin Detemir Brand 11 $3,446

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$169,125

Of which drugs: $7,078

Medicare patients

213

Average age 76

Services billed

4,870

110 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 38%
Ischemic heart disease 28%
Chronic kidney disease 20%
Depression 16%
Osteoporosis 14%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 41 41 $878
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 45 109 $95

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
RYBELSUS
  • Novo Nordisk Inc $29
$29 — —
Ozempic
  • Novo Nordisk Inc $29
$29 20 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $28
$28 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record